Report from Annual General Meeting of Vitrolife AB (publ)
At Vitrolife’s Annual General Meeting today, the following, amongst other things, was decided:
- The Board’s proposed dividend of SEK 0.85 per share for the financial year 2018 was approved. Monday May 6, 2019 was adopted as the record day.
- Re-election of Board members Barbro Fridén, Lars Holmqvist, Pia Marions and Jón Sigurdsson and new election of Henrik Blomquist, in accordance with the election committee’s proposal. Jón Sigurdsson was elected Chairman of the Board (new election).
- Remuneration to the members of the Board shall be totalling SEK 2,165,000, of which SEK 825,000 to the Chairman of the Board, SEK 275,000 to each of the other members of the Board, SEK 60,000 to the Chairman of the Audit Committee, SEK 60,000 to the Chairman of the Remuneration Committee and SEK 30,000 to the other members of these committees.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to take a decision on the issue of a maximum of 10,850,000 shares in total, corresponding to just below 10 percent of the company’s share capital.
- The Board was authorized to take a decision, up until the next Annual General Meeting and on one or more occasions, with regard to the acquisition of the company’s own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.
- The proposed principles for remuneration and other conditions of employment for the senior management were approved.
Gothenburg, May 2, 2019
VITROLIFE AB (publ)
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7.30 pm CET on May 2, 2019.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.
Vitrolife has approximately 390 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: email@example.com. Website: www.vitrolife.com/